List view / Grid view
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
12 April 2016 | By Victoria White, Digital Content Producer
Everolimus for advanced breast cancer, savuconazole for invasive aspergillosis and mucormycosis, and camellia sinensis for genital warts were all accepted...
7 March 2016 | By Victoria White
The Scottish Medicines Consortium (SMC) has accepted three new medicines for routine use in NHS Scotland.
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
12 October 2015 | By Victoria White
The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis
13 July 2015 | By Victoria White
The SMC has announced that sorafenib has been accepted for use within NHS Scotland for the treatment of patients with thyroid carcinoma...
